A multi-centre, double-blind randomized study to assess the efficacy and tolerance of sulindac versus placebo in the symptomatic treatment of patients with upper respiratory tract infection.
A multi-centre, double-blind, randomized, placebo-controlled study was carried out to compare the efficacy and tolerance of sulindac (200 mg twice daily) with placebo in the symptomatic treatment for 7 days of 312 adult patients with upper respiratory tract infection. Investigators and patients rated sulindac superior to placebo in the overall evaluations of response to treatment, but the differences were not significant. In general, patients treated with sulindac had greater mean decreases from baseline scores for individual signs and symptoms than did placebo patients. Fever was relieved better by sulindac than by placebo. The mean decrease from baseline pain scores was also greater in the sulindac group. More patients receiving sulindac reported clinical adverse experiences compared with those on placebo, the most common adverse experiences reported being in the digestive system.
D000328:Adult; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D007192:Indenes / Q000627:therapeutic use*; D008297:Male; D010919:Placebos; D011897:Random Allocation; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D013467:Sulindac / Q000627:therapeutic use* / Q000633:toxicity
D007192:Indenes; D010919:Placebos; D013467:Sulindac